Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review

Chimeric antigen receptor T-cell therapy (CAR-T) has been widely applied in the clinical practice of relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) due to its promising effects. Hyperprogressive disease (HPD) has gained attention for rapid tumor progression and has become a therapeut...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Jiajie He, Rui Zou, Liqing Kang, Lingzi Yu, Peng Wang, Yang Shao, Junheng Liang, Depei Wu, Zhengming Jin, Changju Qu
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2023-11-01
Reeks:	Frontiers in Oncology
Onderwerpen:	hyperprogressive disease (HPD) circulating tumor DNA (ctDNA) chimeric antigen receptor T cell therapy (CAR-T) diffuse large B-cell lymphoma (DLBCL) pseudoprogression
Online toegang:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1283194/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!